Sarepta Therapeutics' gene therapy for Duchenne muscular dystrophy is on hold due to safety issues. An FDA official warns the path to market approval is fraught with challenges, especially after patient deaths linked to liver injuries.
Breakingon.com is an independent news platform that delivers the latest news, trends, and analyses quickly and objectively. We gather and present the most important developments from around the world and local sources with accuracy and reliability. Our goal is to provide our readers with factual, unbiased, and comprehensive news content, making information easily accessible.
Stay informed with us!
